Precision Oncology Technologies Market Analysis and Forecast to 2034

Published Jul 22, 2025

Length 305 Pages

SKU # GIS20212816

Description

The Precision Oncology Technologies Market is a cutting-edge sector within medical technology, tailored specifically for cancer treatment through molecular and genomic analysis. This market focuses on developing treatments that are finely attuned to the genetic makeup of individual tumors, thereby enhancing treatment efficacy and reducing side effects. The use of advanced technologies such as genomics and artificial intelligence is pivotal in identifying unique cancer signatures and devising personalized therapeutic strategies. This market is expanding rapidly, driven by an increase in cancer prevalence worldwide and technological advancements that have made genomic testing more accessible and affordable. These developments have led to a surge in personalized treatment plans, with precision oncology at the forefront, ensuring treatments are more targeted and effective. Precision oncology technologies find applications in both diagnostics and therapeutics. Diagnostically, they help pinpoint specific genetic mutations and biomarkers to tailor treatment paths. Therapeutically, they are instrumental in the creation of drugs and treatment modalities that specifically target these genetic variations. The synergy between biotech firms, pharmaceutical companies, and academic entities further accelerates innovation in this field, enhancing the precision of diagnostics and broadening the therapeutic applications of this technology.

Key Market Drivers

Drivers in the Precision Oncology Technologies Market include: Technological Advancements: Continuous innovations in genomic sequencing and bioinformatics have significantly enhanced the accuracy and speed of tumor profiling, driving demand for precision oncology solutions. Increased Cancer Prevalence: The rising global incidence of cancer boosts the need for personalized treatment approaches, thereby propelling the precision oncology market. Government and Regulatory Support: Enhanced support and funding from governments for cancer research, coupled with favorable regulatory policies for precision medicine, facilitate market growth. Expansion of Targeted Therapies: The development and approval of targeted therapies, which require companion diagnostics, are crucial for the deployment of precision oncology practices. Healthcare IT Integration: The integration of advanced IT solutions with healthcare systems enables the efficient handling of large genomic datasets, which is vital for the implementation of precision oncology protocols.

Key Restraints and Challenges

Key Market Restraints for the Precision Oncology Technologies Market: Regulatory and Reimbursement Challenges: Stringent regulations and uncertain reimbursement policies can inhibit the adoption of new technologies in precision oncology, delaying market entry and innovation. High Cost of Precision Medicine: The significant costs associated with genomic testing and targeted therapies can limit their accessibility and adoption, particularly in underfunded healthcare systems. Complexity of Tumor Profiles: The high variability and complexity of cancer tumor profiles demand advanced, yet costly, technologies for accurate analysis, which can be a barrier for widespread implementation. Data Privacy and Security Concerns: The handling of sensitive genetic information raises significant data privacy and security issues, potentially restraining patient willingness to undergo genetic testing. Lack of Adequate Healthcare Infrastructure: Inadequate healthcare infrastructure in developing countries can restrict the effective implementation and scalability of precision oncology solutions, limiting market growth in these regions.

Key Players

Guardant Health, Foundation Medicine, Caris Life Sciences, Tempus, Natera, Neo Genomics, Personalis, Adaptive Biotechnologies, Biodesix, Invitae, Onco Cyte, Freenome, Grail, Helix, Bristol Myers Squibb, Illumina, Strata Oncology, Genomic Health, Oncocyte Corporation, Epic Sciences, Illumina, Thermo Fisher Scientific, Agilent Technologies, Roche Molecular Systems, QIAGEN, Foundation Medicine, Myriad Genetics, Guardant Health, Exact Sciences, Bio-Rad Laboratories, GE Healthcare, Siemens Healthineers, Philips, Novartis, AstraZeneca, Bristol-Myers Squibb, Merck, Pfizer, Johnson & Johnson, Bayer

Research Scope:

Estimates and forecasts the overall market size across type, application, and region.
Provides detailed information and key takeaways on qualitative and quantitative trends, dynamics, business framework, competitive landscape, and company profiling.
Identifies factors influencing market growth and challenges, opportunities, drivers, and restraints.
Identifies factors that could limit company participation in international markets to help calibrate market share expectations and growth rates.
Evaluates key development strategies like acquisitions, product launches, mergers, collaborations, business expansions, agreements, partnerships, and R&D activities.
Analyzes smaller market segments strategically, focusing on their potential, growth patterns, and impact on the overall market.
Outlines the competitive landscape, assessing business and corporate strategies to monitor and dissect competitive advancements.

Our research scope provides comprehensive market data, insights, and analysis across a variety of critical areas. We cover Local Market Analysis, assessing consumer demographics, purchasing behaviors, and market size within specific regions to identify growth opportunities. Our Local Competition Review offers a detailed evaluation of competitors, including their strengths, weaknesses, and market positioning. We also conduct Local Regulatory Reviews to ensure businesses comply with relevant laws and regulations. Industry Analysis provides an in-depth look at market dynamics, key players, and trends. Additionally, we offer Cross-Segmental Analysis to identify synergies between different market segments, as well as Production-Consumption and Demand-Supply Analysis to optimize supply chain efficiency. Our Import-Export Analysis helps businesses navigate global trade environments by evaluating trade flows and policies. These insights empower clients to make informed strategic decisions, mitigate risks, and capitalize on market opportunities.

What to expect in the report:

Assess and project the market size for the Adaptive Reuse Architecture sector, segmented by type, application, and geography

Provide detailed insights and essential takeaways on qualitative and quantitative trends, market dynamics, structural framework, competitive landscape, and company profiling
Identify key factors driving market growth, alongside challenges, opportunities, drivers, and restraints
Determine elements that may constrain company involvement in international markets, aiding in the calibration of market share expectations and growth rates
Track and evaluate strategic developments such as acquisitions, product launches, mergers, collaborations, business expansions, agreements, partnerships, and R&D activities
Conduct a strategic analysis of smaller market segments, emphasizing their potential, unique growth patterns, and impact on the broader market
Elucidate the competitive landscape, including an evaluation of business and corporate strategies, to monitor and analyze competitive progressions
Identify leading market participants based on business objectives, geographic presence, product offerings, and strategic initiatives

Chapter : 1: Sections : 1.1 Market Definition; 1.2 Market Segmentation; 1.3 Regional Coverage; 1.4 Key Company Profiles; 1.5 Key Manufacturers Profiles; 1.6 Data Snapshot : Executive Summary
Chapter : 2: Sections : 2.1 Summary; 2.2 Key Opinion Leaders; 2.3 Key Highlights of the Market, by Type; 2.4 Key Highlights of the Market, by Product; 2.5 Key Highlights of the Market, by Services; 2.6 Key Highlights of the Market, by Technology; 2.7 Key Highlights of the Market, by Application; 2.8 Key Highlights of the Market, by End user; 2.9 Key Highlights of the Market, by Component; 2.10 Key Highlights of the Market, by Deployment; 2.11 Key Highlights of the Market, by Stage; 2.12 Key Highlights of the Market, by North America; 2.13 Key Highlights of the Market, by Europe; 2.14 Key Highlights of the Market, by Asia-Pacific; 2.15 Key Highlights of the Market, by Latin America; 2.16 Key Highlights of the Market, by Middle East; 2.17 Key Highlights of the Market, by Africa : Premium Insights on the Market
Chapter : 3: Sections : 3.1 Market Attractiveness Analysis, by Region; 3.2 Market Attractiveness Analysis, by Type; 3.3 Market Attractiveness Analysis, by Product; 3.4 Market Attractiveness Analysis, by Services; 3.5 Market Attractiveness Analysis, by Technology; 3.6 Market Attractiveness Analysis, by Application; 3.7 Market Attractiveness Analysis, by End user; 3.8 Market Attractiveness Analysis, by Component; 3.9 Market Attractiveness Analysis, by Deployment; 3.10 Market Attractiveness Analysis, by Stage; 3.11 Market Attractiveness Analysis, by North America; 3.12 Market Attractiveness Analysis, by Europe; 3.13 Market Attractiveness Analysis, by Asia-Pacific; 3.14 Market Attractiveness Analysis, by Latin America; 3.15 Market Attractiveness Analysis, by Middle East; 3.16 Market Attractiveness Analysis, by Africa : Market Analysis
Chapter : 4: Sections : 4.1 Market Drivers; 4.2 Market Trends; 4.3 Market Restraints; 4.4 Market Opportunities; 4.5 Porters Five Forces Analysis; 4.6 PESTLE Analysis; 4.7 Value Chain Analysis; 4.8 4Ps Model; 4.9 ANSOFF Matrix : Market Strategy
Chapter : 5: Sections : 5.1 Parent Market Analysis; 5.2 Supply-Demand Analysis; 5.3 Consumer Buying Interest; 5.4 Case Study Analysis; 5.5 Pricing Analysis; 5.6 Regulatory Landscape; 5.7 Supply Chain Analysis; 5.8 Competition Product Analysis; 5.9 Recent Developments : Market Size
Chapter : 6: Sections : 6.1 Precision Oncology Technologies Market Market Size, by Value; 6.2 Precision Oncology Technologies Market Market Size, by Volume : Precision Oncology Technologies Market Market, by Type
Chapter : 7: Sections : 7.1 Key Market Overview, Trends & Opportunity Analysis; 7.2 Market Size and Forecast, by Type; 7.2.1 Market Size and Forecast, by Diagnostics; 7.2.1 Market Size and Forecast, by Therapeutics; 7.2.1 Market Size and Forecast, by Prognostics; 7.2.1 Market Size and Forecast, by Predictive Biomarkers; 7.3 Market Size and Forecast, by Product; 7.3.1 Market Size and Forecast, by Genetic Tests; 7.3.1 Market Size and Forecast, by Companion Diagnostics; 7.3.1 Market Size and Forecast, by Liquid Biopsy; 7.3.1 Market Size and Forecast, by Next-Generation Sequencing; 7.3.1 Market Size and Forecast, by Immunohistochemistry; 7.3.1 Market Size and Forecast, by Fluorescence In Situ Hybridization; 7.4 Market Size and Forecast, by Services; 7.4.1 Market Size and Forecast, by Consultation; 7.4.1 Market Size and Forecast, by Genomic Profiling; 7.4.1 Market Size and Forecast, by Data Interpretation; 7.4.1 Market Size and Forecast, by Clinical Trial Services; 7.5 Market Size and Forecast, by Technology; 7.5.1 Market Size and Forecast, by Gene Sequencing; 7.5.1 Market Size and Forecast, by Polymerase Chain Reaction; 7.5.1 Market Size and Forecast, by Microarray; 7.5.1 Market Size and Forecast, by Bioinformatics; 7.5.1 Market Size and Forecast, by Nanotechnology; 7.6 Market Size and Forecast, by Application; 7.6.1 Market Size and Forecast, by Breast Cancer; 7.6.1 Market Size and Forecast, by Lung Cancer; 7.6.1 Market Size and Forecast, by Colorectal Cancer; 7.6.1 Market Size and Forecast, by Prostate Cancer; 7.6.1 Market Size and Forecast, by Melanoma; 7.6.1 Market Size and Forecast, by Leukemia; 7.7 Market Size and Forecast, by End user; 7.7.1 Market Size and Forecast, by Hospitals; 7.7.1 Market Size and Forecast, by Diagnostic Laboratories; 7.7.1 Market Size and Forecast, by Research Institutes; 7.7.1 Market Size and Forecast, by Pharmaceutical Companies; 7.7.1 Market Size and Forecast, by Biotechnology Firms; 7.8 Market Size and Forecast, by Component; 7.8.1 Market Size and Forecast, by Software; 7.8.1 Market Size and Forecast, by Hardware; 7.8.1 Market Size and Forecast, by Reagents; 7.8.1 Market Size and Forecast, by Kits; 7.8.1 Market Size and Forecast, by Consumables; 7.9 Market Size and Forecast, by Deployment; 7.9.1 Market Size and Forecast, by On-Premises; 7.9.1 Market Size and Forecast, by Cloud-Based; 7.9.1 Market Size and Forecast, by Hybrid; 7.10 Market Size and Forecast, by Stage; 7.10.1 Market Size and Forecast, by Early-Stage Cancer; 7.10.1 Market Size and Forecast, by Advanced-Stage Cancer; 7.10.1 Market Size and Forecast, by Recurrent Cancer : Precision Oncology Technologies Market Market, by Region
Chapter : 8: Sections : 8.1 Overview; 8.2 North America; 8.3.1 Key Market Trends and Opportunities; 8.3.2 North America Market Size and Forecast, by Type; 8.3.3 North America Market Size and Forecast, by Diagnostics; 8.3.4 North America Market Size and Forecast, by Therapeutics; 8.3.5 North America Market Size and Forecast, by Prognostics; 8.3.6 North America Market Size and Forecast, by Predictive Biomarkers; 8.3.7 North America Market Size and Forecast, by Product; 8.3.8 North America Market Size and Forecast, by Genetic Tests; 8.3.9 North America Market Size and Forecast, by Companion Diagnostics; 8.3.10 North America Market Size and Forecast, by Liquid Biopsy; 8.3.11 North America Market Size and Forecast, by Next-Generation Sequencing; 8.3.12 North America Market Size and Forecast, by Immunohistochemistry; 8.3.13 North America Market Size and Forecast, by Fluorescence In Situ Hybridization; 8.3.14 North America Market Size and Forecast, by Services; 8.3.15 North America Market Size and Forecast, by Consultation; 8.3.16 North America Market Size and Forecast, by Genomic Profiling; 8.3.17 North America Market Size and Forecast, by Data Interpretation; 8.3.18 North America Market Size and Forecast, by Clinical Trial Services; 8.3.19 North America Market Size and Forecast, by Technology; 8.3.20 North America Market Size and Forecast, by Gene Sequencing; 8.3.21 North America Market Size and Forecast, by Polymerase Chain Reaction; 8.3.22 North America Market Size and Forecast, by Microarray; 8.3.23 North America Market Size and Forecast, by Bioinformatics; 8.3.24 North America Market Size and Forecast, by Nanotechnology; 8.3.25 North America Market Size and Forecast, by Application; 8.3.26 North America Market Size and Forecast, by Breast Cancer; 8.3.27 North America Market Size and Forecast, by Lung Cancer; 8.3.28 North America Market Size and Forecast, by Colorectal Cancer; 8.3.29 North America Market Size and Forecast, by Prostate Cancer; 8.3.30 North America Market Size and Forecast, by Melanoma; 8.3.31 North America Market Size and Forecast, by Leukemia; 8.3.32 North America Market Size and Forecast, by End user; 8.3.33 North America Market Size and Forecast, by Hospitals; 8.3.34 North America Market Size and Forecast, by Diagnostic Laboratories; 8.3.35 North America Market Size and Forecast, by Research Institutes; 8.3.36 North America Market Size and Forecast, by Pharmaceutical Companies; 8.3.37 North America Market Size and Forecast, by Biotechnology Firms; 8.3.38 North America Market Size and Forecast, by Component; 8.3.39 North America Market Size and Forecast, by Software; 8.3.40 North America Market Size and Forecast, by Hardware; 8.3.41 North America Market Size and Forecast, by Reagents; 8.3.42 North America Market Size and Forecast, by Kits; 8.3.43 North America Market Size and Forecast, by Consumables; 8.3.44 North America Market Size and Forecast, by Deployment; 8.3.45 North America Market Size and Forecast, by On-Premises; 8.3.46 North America Market Size and Forecast, by Cloud-Based; 8.3.47 North America Market Size and Forecast, by Hybrid; 8.3.48 North America Market Size and Forecast, by Stage; 8.3.49 North America Market Size and Forecast, by Early-Stage Cancer; 8.3.50 North America Market Size and Forecast, by Advanced-Stage Cancer; 8.3.51 North America Market Size and Forecast, by Recurrent Cancer; 8.3.52 United States; 8.3.53 United States Market Size and Forecast, by Type; 8.3.54 United States Market Size and Forecast, by Diagnostics; 8.3.55 United States Market Size and Forecast, by Therapeutics; 8.3.56 United States Market Size and Forecast, by Prognostics; 8.3.57 United States Market Size and Forecast, by Predictive Biomarkers; 8.3.58 United States Market Size and Forecast, by Product; 8.3.59 United States Market Size and Forecast, by Genetic Tests; 8.3.60 United States Market Size and Forecast, by Companion Diagnostics; 8.3.61 United States Market Size and Forecast, by Liquid Biopsy; 8.3.62 United States Market Size and Forecast, by Next-Generation Sequencing; 8.3.63 United States Market Size and Forecast, by Immunohistochemistry; 8.3.64 United States Market Size and Forecast, by Fluorescence In Situ Hybridization; 8.3.65 United States Market Size and Forecast, by Services; 8.3.66 United States Market Size and Forecast, by Consultation; 8.3.67 United States Market Size and Forecast, by Genomic Profiling; 8.3.68 United States Market Size and Forecast, by Data Interpretation; 8.3.69 United States Market Size and Forecast, by Clinical Trial Services; 8.3.70 United States Market Size and Forecast, by Technology; 8.3.71 United States Market Size and Forecast, by Gene Sequencing; 8.3.72 United States Market Size and Forecast, by Polymerase Chain Reaction; 8.3.73 United States Market Size and Forecast, by Microarray; 8.3.74 United States Market Size and Forecast, by Bioinformatics; 8.3.75 United States Market Size and Forecast, by Nanotechnology; 8.3.76 United States Market Size and Forecast, by Application; 8.3.77 United States Market Size and Forecast, by Breast Cancer; 8.3.78 United States Market Size and Forecast, by Lung Cancer; 8.3.79 United States Market Size and Forecast, by Colorectal Cancer; 8.3.80 United States Market Size and Forecast, by Prostate Cancer; 8.3.81 United States Market Size and Forecast, by Melanoma; 8.3.82 United States Market Size and Forecast, by Leukemia; 8.3.83 United States Market Size and Forecast, by End user; 8.3.84 United States Market Size and Forecast, by Hospitals; 8.3.85 United States Market Size and Forecast, by Diagnostic Laboratories; 8.3.86 United States Market Size and Forecast, by Research Institutes; 8.3.87 United States Market Size and Forecast, by Pharmaceutical Companies; 8.3.88 United States Market Size and Forecast, by Biotechnology Firms; 8.3.89 United States Market Size and Forecast, by Component; 8.3.90 United States Market Size and Forecast, by Software; 8.3.91 United States Market Size and Forecast, by Hardware; 8.3.92 United States Market Size and Forecast, by Reagents; 8.3.93 United States Market Size and Forecast, by Kits; 8.3.94 United States Market Size and Forecast, by Consumables; 8.3.95 United States Market Size and Forecast, by Deployment; 8.3.96 United States Market Size and Forecast, by On-Premises; 8.3.97 United States Market Size and Forecast, by Cloud-Based; 8.3.98 United States Market Size and Forecast, by Hybrid; 8.3.99 United States Market Size and Forecast, by Stage; 8.3.100 United States Market Size and Forecast, by Early-Stage Cancer; 8.3.101 United States Market Size and Forecast, by Advanced-Stage Cancer; 8.3.102 United States Market Size and Forecast, by Recurrent Cancer; 8.3.103 Local Competition Analysis; 8.3.104 Local Market Analysis : Competitive Landscape
Chapter : 9: Sections : 9.1 Overview; 9.2 Market Share Analysis; 9.3 Key Player Positioning; 9.4 Competitive Leadership Mapping; 9.5 Star Players; 9.6 Innovators; 9.7 Emerging Players; 9.8 Vendor Benchmarking; 9.9 Developmental Strategy Benchmarking; 9.10 New Product Developments; 9.11 Product Launches; 9.12 Business Expansions; 9.13 Partnerships, Joint Ventures, and Collaborations; 9.14 Mergers and Acquisitions : Company Profiles - Overview, Segments, Performance, Products, Key Strategies, SWOT Analysis
Chapter : 10: Sections : 10.1 Guardant Health; 10.2 Foundation Medicine; 10.3 Caris Life Sciences; 10.4 Tempus; 10.5 Natera; 10.6 Neo Genomics; 10.7 Personalis; 10.8 Adaptive Biotechnologies; 10.9 Biodesix; 10.10 Invitae; 10.11 Onco Cyte; 10.12 Freenome; 10.13 Grail; 10.14 Helix; 10.15 Bristol Myers Squibb; 10.16 Illumina; 10.17 Strata Oncology; 10.18 Genomic Health; 10.19 Oncocyte Corporation; 10.20 Epic Sciences; 10.21 Illumina; 10.22 Thermo Fisher Scientific; 10.23 Agilent Technologies; 10.24 Roche Molecular Systems; 10.25 QIAGEN; 10.26 Foundation Medicine; 10.27 Myriad Genetics; 10.28 Guardant Health; 10.29 Exact Sciences; 10.30 Bio-Rad Laboratories; 10.31 GE Healthcare; 10.32 Siemens Healthineers; 10.33 Philips; 10.34 Novartis; 10.35 AstraZeneca; 10.36 Bristol-Myers Squibb; 10.37 Merck; 10.38 Pfizer; 10.39 Johnson & Johnson; 10.40 Bayer; 10.41

Pricing

Currency Rates

Single User Email from Publisher $4,750
Global Site License Email from Publisher $6,750

How Do Licenses Work?

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.

Chat Now